Pharmacopeia has officially launched its software subsidiary, uniting Molecular Simulations, Synopsys Scientific Systems, Oxford Molecular, and the Genetics Computer Group under the name of Accelrys.
The unit will begin operating under the new name on June 1.
Mike Stapleton, COO of the subsidiary, unveiled the name, structure, and objectives of Accelrys at the American Chemical Society meeting in San Diego on April 2. “Our vision is of an integrated software platform supporting enterprise-wide R&D decisions,” Stapleton said.
Accelrys will continue to offer a range of software tools for simulation, bioinformatics, cheminformatics, workflow management, and decision support. The new unit will also help to support Pharmacopeia’s drug discovery efforts.
Pharmacopeia also said that Accelrys would have a new group dedicated to providing consulting services.
Pharmacopeia spokeswoman Sue Rodney said the consulting business would help Accelrys create an integrated solution for its software clients. “It will be offering a solution as opposed to individual, isolated applications that we were selling up until now.”
The consulting staff currently comprises a “handful” of people, Rodney said, which would be increased as demand requires. Revenue estimates for the consulting unit are on the order of several million dollars at first, “but as we make further progress integrating the recent acquisitions into our existing business, we’ll certainly have more capabilities to offer our customers,” Rodney said.
Accelrys demonstrated several new chemical software products last week and will be releasing updated versions of the Wisconsin package and other bioinformatics products as well as new bioinformatics offerings in the coming months.
Accelrys has over 500 employees located in San Diego, Calif., Princeton, NJ, Madison, Wis., and Cambridge and Leeds, UK. It will be based in San Diego and Cambridge.
The unit’s four subsidiaries had pro forma revenues of more than $90 million in 2000, or 76 percent of Pharmacopeia’s overall revenues of $119 million.